/Funding
News & insights
What we are working on
Milestones, partnerships and short notes on the spondyloarthritis treatment landscape from the P3 Therapeutics team.
/Funding
GATEWAY: a EUROSTARS 4 application for a gut-entheseal organ-on-chip platform
P3 Therapeutics and its European partners have applied to EUROSTARS 4 with project 12259-GATEWAY: a 2D and 3D humanised gut-entheseal organ-on-chip platform for testing a new class of anti-inflammatory small chemical molecules.
/Funding
P3 Therapeutics is supported by the European Union under the InvestEU Fund
Non-dilutive European funding, stacked with seed equity, is part of how P3T stays capital-efficient while it completes preclinical development.
/Science
Six triple-target molecules synthesised and now in in vitro testing
After encouraging in-silico results, six TTA small chemical molecules have been synthesised, with 15 more pending, and are now in in vitro testing.
/Funding
Vesna VC backs P3 Therapeutics
Southeast European deep-tech fund Vesna VC has invested in P3 Therapeutics, backing our multi-target approach to chronic inflammation. Financial terms were not disclosed.